OGT expands commitment to improved cancer profiling with CCMC agreement
Will design a whole genome, cancer-specific microarray
Oxford Gene Technology (OGT), a provider of genetics research and biomarker solutions to advance molecular medicine, has signed a licence agreement with the Cancer Cytogenomics Microarray Consortium (CCMC) to design a whole genome, cancer-specific microarray.
The array will incorporate probes for more than 500 cancer genes and 130 cancer-associated genomic regions from the CCMC’s design for haematological and solid tumours. The aim is to improve cancer research through the accurate identification of DNA copy number changes, and loss of heterozygosity associated with different cancer types.
The agreement is founded on OGT’s development and commercialisation of the CytoSure Haematological Cancer +SNP Array targeting the four common haematological cancers: chronic lymphocytic leukaemia, multiple myeloma, myeloproliferative neoplasms and myelodysplastic syndrome and is a further extension of the company’s work in cancer research.
As lead partner in a £1.16 million grant from the UK government-backed Technology Strategy Board, OGT is also developing a next generation sequencing tumour profiling assay, which will provide specific information about individual cancer samples to facilitate research into personalised treatment strategies.
The company also has a rich portfolio of biomarkers for early stage cancer detection with advanced programmes in colorectal and prostate cancer.
